MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Country |
 USA |
IPO year |
- |
Industry |
Diagnostics research |
Stock Exchange |
NYSESPB |
Shares |
377 M |
Market Cap[1] |
$ 189 B |
EBITDA (LTM) |
$ 8.38 B |
P/E (LTM) |
30.24 |
P/S (LTM) |
4.46 |
EPS (LTM) |
16.81 |
Thermo Fisher Scientific is a globally leading company in the life science industry, focusing on the development and manufacturing of products and services for research, diagnostics, and drug production. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
Thermo Fisher Scientific offers a wide range of products, including laboratory equipment, reagents, consumables, software, and services. The company serves customers in the pharmaceutical and biotech, diagnostics, academic research, and government sectors.
The mission of Thermo Fisher Scientific is to help its customers make the world healthier, cleaner, and safer. The company is also committed to sustainability and aims to reduce its greenhouse gas emissions by 50% by 2030.
Thermo Fisher Scientific is known for its innovation and has received numerous awards for its products and technologies. The company has also made several acquisitions to expand its product offerings and strengthen its presence in different regions.
Overall, is a leading company in the life science industry that is committed to innovation, sustainability, and customer satisfaction. Its products and services have a positive impact on the health and well-being of people around the world.
Other stocks of industry "Diagnostics research"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
$ 2.83 | -4.39 % | $ 91.8 K | Nasdaq Capital Market | USA |
 |
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | Nasdaq Global Market |  Germany |
 |
Agilent Technologies
A
|
$ 116.37 | -1.49 % | $ 35.4 B | NYSE,SPB | USA |
 |
Celcuity
CELC
|
$ 105.97 | -2.15 % | $ 4.18 B | Nasdaq Global Select Market | USA |
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | Nasdaq Capital Market |  Canada |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Nasdaq Global Select Market |  Britain |
 |
Charles River Laboratories International
CRL
|
$ 173.71 | -2.76 % | $ 8.61 B | NYSE,SPB | USA |
 |
Castle Biosciences
CSTL
|
$ 27.4 | -2.11 % | $ 761 M | Nasdaq Global Market,SPB | USA |
 |
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | Nasdaq Capital Market,SPB | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | Nasdaq Global Select Market | USA |
 |
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | NYSE |  China |
 |
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | Nasdaq Global Select Market | USA |
 |
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | Nasdaq Capital Market |  Australia |
 |
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | Nasdaq Global Market | China |
 |
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | Nasdaq Global Select Market | USA |
|
Biodesix
BDSX
|
$ 15.93 | 1.14 % | $ 2.07 B | Nasdaq Global Market | USA |
 |
Fulgent Genetics
FLGT
|
$ 13.83 | -2.61 % | $ 418 M | Nasdaq Global Market | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | Nasdaq Capital Market | USA |
 |
BioNano Genomics
BNGO
|
$ 1.11 | -3.07 % | $ 1.41 M | Nasdaq Capital Market,SPB | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 205.94 | -2.06 % | $ 22.9 B | NYSE,SPB | USA |
 |
Danaher Corporation
DHR
|
$ 202.02 | -1.88 % | $ 144 B | NYSE,SPB | USA |
 |
Exact Sciences Corporation
EXAS
|
$ 103.3 | -0.05 % | $ 19.5 B | Nasdaq Capital Market,SPB | USA |
 |
Bioventus
BVS
|
$ 8.64 | -1.48 % | $ 541 M | Nasdaq Global Select Market | USA |
 |
DarioHealth Corp.
DRIO
|
$ 10.5 | -2.33 % | $ 298 M | Nasdaq Capital Market |  Israel |
 |
DexCom
DXCM
|
$ 73.05 | -1.0 % | $ 28.5 B | Nasdaq Global Select Market,SPB | USA |
 |
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | NYSE |  Niderland |
 |
Burning Rock Biotech Limited
BNR
|
$ 24.2 | -3.82 % | $ 258 M | Nasdaq Global Market | China |
 |
CareDx, Inc
CDNA
|
$ 18.27 | -2.53 % | $ 974 M | Nasdaq Global Market,SPB | USA |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | Nasdaq Capital Market | USA |
 |
ICON Public Limited Company
ICLR
|
$ 105.46 | -2.6 % | $ 8.7 B | Nasdaq Global Select Market,SPB |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
$ 642.76 | 0.95 % | $ 51.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | Nasdaq Capital Market | Israel |
 |
Illumina
ILMN
|
$ 128.99 | -2.93 % | $ 20.5 B | Nasdaq Global Select Market,SPB | USA |
 |
Guardant Health
GH
|
$ 90.81 | -1.54 % | $ 11.4 B | Nasdaq Global Select Market,SPB | USA |
 |
IQVIA Holdings
IQV
|
$ 171.78 | -1.43 % | $ 29.5 B | NYSE,SPB | USA |
 |
Brainsway Ltd.
BWAY
|
$ 22.69 | -4.22 % | $ 99.4 M | Nasdaq Global Select Market | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
$ 280.06 | -2.17 % | $ 23.3 B | NYSE,SPB | USA |
 |
Co-Diagnostics
CODX
|
- | - | $ 79.8 M | Nasdaq Capital Market | USA |
 |
Lantheus Holdings
LNTH
|
$ 77.65 | 1.77 % | $ 5.24 B | Nasdaq Global Select Market,SPB | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | Nasdaq Capital Market,SPB | USA |
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | NYSE | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 309.79 | -1.0 % | $ 27 B | NYSE,SPB |  Schweiz |
 |
Myriad Genetics
MYGN
|
$ 4.93 | -1.6 % | $ 457 M | Nasdaq Global Select Market,SPB | USA |
 |
NeoGenomics
NEO
|
$ 9.13 | -3.89 % | $ 1.17 B | Nasdaq Global Select Market,SPB | USA |
 |
Natera
NTRA
|
$ 200.13 | 0.2 % | $ 19.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Pacific Biosciences of California
PACB
|
$ 1.51 | -7.1 % | $ 453 M | Nasdaq Global Select Market,SPB | USA |
 |
Neogen Corporation
NEOG
|
$ 10.97 | -1.61 % | $ 2.38 B | Nasdaq Global Select Market,SPB | USA |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | Nasdaq Capital Market,SPB | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | Nasdaq Capital Market | USA |
 |
Precipio
PRPO
|
$ 24.5 | -0.73 % | $ 31.8 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.